Rubin Steven D 4

What Happened Steven D. Rubin, a director of Eloxx Pharmaceuticals, was granted a derivative award covering 4,018 shares on 2026-06-08. The Form 4 reports an acquisition price of $0.00 (derivative award), so no cash was paid at grant and no immediate sale or purchase occurred.

Key Details

• Transaction date: 2026-06-08; Form 4 filed: 2026-06-10.
• Award: 4,018 shares (derivative), reported price $0.00 (acquired value $0).
• Shares owned after transaction: not specified in the provided details.
• Footnote: the award is a stock option that vests in 24 substantially equal monthly installments and will be fully vested and exercisable on the second anniversary of the grant date, subject to continuous service (Footnote F1).
• No indication in the supplied data that the filing was late.

Context This filing documents a grant/award (not an open-market buy or a sale). Because it’s a time‑based vesting award, the economic interest and voting power typically don’t change until vesting or exercise. The reported $0.00 acquisition price and the footnote indicate these are stock-option style awards with a two‑year vesting schedule; check company disclosures for the exact award type and exercise terms if you need further detail.